BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data. METHODS: The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), 36-Item Short Form Health Survey (SF-36), and Pediatric Quality of Life Inventory measures were administered before HCT, on day 100, and at 6 and 12 months. Patients were recruited by the transplant center, but posttransplant PRO collection was managed centrally by the CIBMTR. RESULTS: There were 580 eligible patients, and 390 (67%) enrolled. Feasibility was shown by high time-specific retention rates (176 of 238 at 1 year or 74%) and participant satisfaction. Factors associated with higher response rates were an age > 50 years (odds ratio [OR], 1.58; 95% confidence interval [CI], 1.03-2.41; P 5.0355), white race (OR, 4.61; 95% CI, 2.66-7.99; P <.0001), and being married (OR, 2.28; 95% CI, 1.42-3.65; P 5.0006) for adults and a higher family income for children (OR, 4.99; 95% CI, 2.12-11.75; P 5.0002). Importantly, pre-HCT PRO scores independently predicted survival after adjustments for patient-, disease-, and transplant-related factors. The adjusted probabilities of 1-year survival were 56%, 67%, 75%, and 76% by increasing quartiles of the pre-HCT FACT-BMT score and 58%, 72%, 62%, and 82% by increasing quartiles of the pre-HCT SF-36 physical component score. CONCLUSIONS: A hybrid model of local consent for centralized PRO collection is feasible, and pretransplant PROs provide critical prognostic information for HCT outcomes.
INTRODUCTION
Although allogeneic hematopoietic cell transplantation (HCT) offers a potential cure to many patients with malignancies or serious blood disorders, a significant risk of late effects and consequent morbidity exists. It is well recognized that patient-reported outcomes (PROs) show alterations after the procedure in comparison with the baseline. Using multidimensional measures, several studies have shown an initial deterioration and a subsequent improvement in PRO scores. 1, 2 Other studies have assessed the transplant-related factors that affect PROs, including posttransplant complications, which adversely affect health-related quality of life (HRQOL). [2] [3] [4] [5] [6] Although it is known that baseline PRO data correlate with cancer survival in general, 7 this relation is not well studied in the HCT setting. A recent prospective, multicenter clinical trial testing an exercise and stress management intervention in HCT patients has shown, however, that baseline PROs significantly predict survival after transplantation, even after adjustments for other pretransplant clinical and demographic factors. 8 Thus, baseline PRO scores have value for prognostication and individualized counseling of patients.
Despite the aforementioned value, broad systematic efforts to collect PRO data alongside the clinical data collected by transplant outcome registries and to link these in large representative data sets have not occurred. Doing so would have numerous benefits for research in this area, including, among other things, the availability of detailed clinical outcomes from the registry, a well-defined patient population (with comprehensively collected demographics and pretransplant characteristics) that is already undergoing extensive medical evaluations, and an existing infrastructure for the collection, collation, and analysis of data. In addition, PROs can be used as a variable in multivariate analyses in this setting.
The Center for International Blood and Marrow Transplant Research (CIBMTR) has been collecting HCT outcome data worldwide for more than 40 years, and this has resulted in a research database including more than 425,000 patients. Information from the database and the support provided by the CIBMTR Coordinating Center to analyze it have led to the successful completion of hundreds of studies led by independent investigators across the transplant and wider biomedical community that have significantly guided clinical practice worldwide.
The overall aim of this study was to assess the feasibility of routinely collecting PRO data via a hybrid model of local consent followed by centralized data collection by the CIBMTR Coordinating Center in the setting of an established outcome registry. A second aim was to correlate these data with the registry clinical data and outcomes.
MATERIALS AND METHODS

Patient Selection, Enrollment, and Assessment Schedule
Seven of a possible 183 transplant centers in the United States participated; 5 enrolled all ages, and 1 each enrolled pediatric or adult patients only. Centers were invited to participate on the basis of the quality of the clinical data submitted to the CIBMTR, their interest in survivorship, and their willingness to enroll and obtain consent from patients for centralized PRO collection. This study was approved by the National Marrow Donor Program Institutional Review Board. All patients who were 2 years old or older and were undergoing allogeneic HCT at these transplant centers were eligible. Patients were required to speak English, have access to a telephone, and have a valid mailing address in the United States. Of 580 eligible patients, 390 (67%) consented and enrolled. The baseline PRO measures were filled out with paper and pencil by patients (and proxies in the case of children) within the 30 days before HCT and were returned to the CIBMTR. The measures, completed 100 days and 6 and 12 months after transplantation, were administered directly by the CIBMTR to the participants by mail. If patients did not return the measure within 3 weeks of the posttransplant time point, up to 3 reminder calls were placed after the CIBMTR confirmed the survival status with the transplant center.
Forms and PRO Measures
CIBMTR study-specific sociodemographic selfreport form Patients (or proxies) reported sociodemographic information at the baseline, including race and ethnicity, marital status, occupation, work status, highest educational grade, health insurance coverage, and household income.
PRO measures
Adults completed the 36-Item Short Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), the most commonly used measures in HCT studies. 9 The SF-36 is a 36-item multidimensional measure that assesses patientreported health and functioning. It takes approximately 5 minutes to complete. From the SF-36, 2 summary domains are calculated: the Physical Component Summary (PCS) scale and the Mental Component Summary (MCS) scale. The normal population mean for the PCS and MCS is 50 with a standard deviation of 10. 10 Higher scores indicate better functioning. The FACT-BMT is a 37-item measure composed of the Functional Assessment of Cancer Therapy-General (FACT-G) plus a transplantspecific subscale. The FACT-G is composed of 4 domains: physical (7 items), social (7 items, including sexual satisfaction), emotional (6 items), and functional (7 items, including work, sleep, and leisure activities). The transplant-specific module includes 10 scored items, including appetite, appearance, mobility, and fatigue. Higher scores indicate better functioning.
11 Children (aged 5-18 years) and proxies (for all children aged 2-18 years) completed the Pediatric Quality of Life Inventory (PedsQL) measurement model, which integrates generic core scales and disease-specific modules into 1 measurement system. 12 The PedsQL is a 23-item measure composed of 4 multidimensional function scales, including physical (8 items), social (5 items), emotional (5 items), and school scales (5 items), which together generate a total summary score. Higher scores indicate better functioning.
Postparticipation satisfaction questionnaire
Patients alive and participating in the study 1 year after transplantation were asked to assess their experience with the study and their willingness to receive future contact.
Statistical Analysis
For both adults and pediatrics, descriptive statistics were used to summarize patient sample characteristics. Categorical variables were summarized with counts and percentages, whereas means and standard deviations were used for continuous variables. The means and standard deviations of the PRO measures were produced at every time point to describe their changes over time. The retention rate was defined as the percentage of patients remaining alive and enrolled at each time point who returned their measure or measures. The response rate was defined as the proportion of the measures completed out of the total number of measures that a patient could have completed. Withdrawal or death, but not relapse, marked the end of the observation window. Binomial regression with the logit link function and with an allowance for overdispersion was used to identify factors associated with a higher proportion of forms completed.
For adults, the baseline FACT-BMT and SF-36 quartiles based on the population sample distribution were used for survival analysis and for evaluating HRQOL at 1 year. A Cox proportional hazards model was used to compare the survival of the patients in different baseline quartiles of the HRQOL measures after adjustments for other significant predictors. Proportionality assumptions were tested before model development. Backward variable elimination procedures were used to identify significant factors to be included in the final model. We accounted for significant covariates when calculating the adjusted survival probabilities used to illustrate patients' survival experience with graphical tools. Linear regression was used to assess the baseline Functional Assessment of Cancer Therapy and SF-36 score effects on the scores from these 2 measures 1 year after transplantation.
In children, the baseline PedsQL score was used as a binary covariate with an established cutoff for ill health 12 (69.7 and 65.4 for child self-report and proxy report, respectively). Kaplan-Meier curves were used to estimate survival probabilities for patients above and below the established cutoffs at the baseline. A Cox regression model was used in an attempt to predict survival on the basis of the PedsQL baseline score and other covariates. Logistic regression predicting the odds of a higher PedsQL score 1 year after transplantation was used.
In regression analyses for all ages, covariates considered in the multivariate models included the following: patient-related variables (age, sex, race/ethnicity, and Karnofsky/Lansky performance and hematopoietic cell transplantation comorbidity index [HCT-CI] scores 13 , disease indications for transplantation, treatment-related variables (conditioning regimen intensity, use of total body irradiation and dosage, stem cell source, donor type, use of anti-thymocyte globulin/Campath, and year of transplantation), and sociodemographic variables (marital status [adults only], education level [adults only], household income, and indicator of rural/urban area). A significance-level a value of .05 was used throughout the study, and all tests were 2-sided. SAS statistical software (SAS Institute, Cary, North Carolina) was used to perform all statistical analyses.
RESULTS
Patients
Time point retention
Three hundred ninety of 580 eligible patients (67%) consented and were enrolled between August 2011 and September 2013. Reasons that patients did not enroll included the following: participating in a different PRO study, being too sick, not being interested in participating in research, and not being approached during the correct time window. Patients remaining alive and enrolled at 100 days, 6 months, and 1 year were sent surveys by postal mail. Of those participants, 45% returned the survey without a reminder, 30% to 50% (at each time point) required 1 reminder, and the remainder received more than 1 reminder. The time-point retention rates at 100 days, 6 months, and 1 year were 69% (223 of 323), 75.8% (213 of 281), and 74% (176 of 238), respectively. The retention rates for adults (173 of 238 or 73%, 163 of 202 or 81%, and 136 of 174 or 78%, respectively) were higher at each time point than those for children (50 of 85 or 59%, 50 of 79 or 63%, and 43 of 72 or 60%, respectively).
Inclusion in analysis (response rate and quality of life)
Of the 390 patients, 347 (89%) submitted sufficient data for analysis. Forty-three patients were excluded because the transplant did not occur (n 5 28), the patient withdrew (n 5 6), the patient returned no measures (n 5 5), or the baseline FACT-BMT or PedsQL score was unscorable (less than half of the measure were completed; n 5 4). Another 7 patients did not return the FACT-BMT or PedsQL at the baseline and were (13) 34 (13) 17 (10) 19 (12) 11 (8) 30-39 y 24 (9) 24 (9) 17 (10) 13 (8) 14 (10) 40-49 y 40 (15) 40 (15) 23 (13) 23 (14) 22 (16) (17) 45 (17) 33 (19) 30 (19) 23 (17) 2 48 (18) 48 (18) 28 (16) 23 (14) 21 (16 In pediatric patients, the only factor associated with a higher response rate in the regression model was a higher family income (OR, 4.99; 95% CI, 2.12-11.75; P 5 .0002). (14) 38 (14) 26 (15) 22 (14) 18 (13 (8) 22 (8) 9 (5) 11 (7) 9 (7) Cord blood 29 (11) 29 (11) 10 (6) 9 (6) The pre-HCT PedsQL self-report or proxy scores were not significantly associated with the response rate.
PRO Measures
Adults
The mean FACT-BMT and SF-36 scores are shown in Table 1 , with the pattern of change over time shown in Table 3 . Patients in the lowest quartile reported improved PRO scores at each posttransplant time point, with a significantly higher score 1 year after transplantation in comparison with the baseline. Conversely, patients in the higher 3 quartiles all reported a drop in their day 100 scores, and this was followed by a gradual increase to nearly the baseline value for quartiles 2 and 3 but to less than the baseline value for quartile 4. The pretransplant FACT-BMT and PCS scores were strongly correlated with the pretransplant Karnofsky performance status (KPS): 80% of the patients in the highest FACT-BMT quartile had a KPS score 90, whereas only 51% in the lowest quartile had a KPS score-90. Similarly, 81% of the patients in the highest PCS quartile had a KPS score 90, and only 39% in the lowest PCS quartile had a KPS score 90. The HCT-CI was not correlated with PROs.
Pediatrics
The mean PedsQL scores are shown in Table 2 . The overall PedsQL score at the baseline was below the cutoff for ill health for the pediatric self-report (67 vs 69.7) but not for the proxy report (65.5 vs 65.4). Children below the cutoff for ill health at the baseline showed a steady increase in PRO scores at each time point, whereas those who started with a high score at the baseline had an initial drop, with a return to nearly the baseline at 1 year. This pattern was similar for the proxy reports (Table 4) . 
Adults
Both the pre-HCT FACT-BMT and the PCS were significantly associated with overall survival after adjustments for patient-, disease-, and transplant-related factors commonly associated with survival after allogeneic HCT (Fig.  1A,B) . The only other factors that retained significance in the model as predictors of lower survival were an older patient age (>55 years) and the use of cord blood as a graft source (Supporting Tables 1 and 2 [see online supporting information]). The MCS at the baseline was not associated with overall survival. We tested whether a higher baseline PRO score predicted better HRQOL after transplantation. In linear regression models, we found that the pre-HCT FACT-BMT and the PCS were associated with the 1-year FACT-BMT and PCS, respectively, after adjustments for other characteristics (data not shown). In addition, the baseline PCS was associated with the FACT-BMT score at 1 year; however, the baseline FACT-BMT was not associated with the 1-year PCS (data not shown).
Pediatrics
Survival probability estimates at 1 and 2 years for the lower scores versus the higher scores of the baseline PedsQL were 79% and 92% and 69% and 92%, respectively (Fig. 1C) . Likewise, the survival probability estimates at 1 and 2 years for the low scores versus the high scores of the baseline proxy reports were 83% and 95% and 77% and 92%, respectively (Fig. 1D) . No other covariates were significant in the model. A higher baseline PRO score was associated with a higher score at 1 year; this was statistically significant for the proxy but not for the self-report (OR for self-report, 6.00; 95% CI, 0.92-39.18; P 5 .0613; OR for proxy report, 15.75; 95% CI, 1.65-150.12; P 5 .0166).
Postparticipation Satisfaction Questionnaire
Survey results are provided in Table 5 . Almost all respondents found the measures easy to complete (89%) and were comfortable doing so (74%); 44% spent 10 minutes or less completing the battery, and 79% felt that paper and pencil were convenient. The highest number of respondents (n 5 94) listed paper and pencil as their response method of choice; however, 46 respondents would prefer that either an online Web site or an e-mail questionnaire be used. Patients contacted by phone felt comfortable, but only half of those answering this question would have been willing to be contacted directly by The data are presented as means and 95% confidence intervals.
Original Article the CIBMTR for study consent and enrollment. Finally, although only 29% reported that completing these measures was helpful to them, 87% reported that they would be willing to complete PRO measures in a routine manner in the future.
DISCUSSION
This study demonstrates that it is feasible to prospectively collect PROs for HCT patients contributing data to an observational database, and these data add prognostic value beyond that provided by traditional clinical, demographic, and transplant factors.
We collected longitudinal PROs for a large proportion of all HCT patients enrolled in the study. Response rates were particularly good (close to 90%) in certain subsets such as older patients, whites, and those who were married. This is similar to data from single-center studies 14, 15 showing high retention rates. We also found factors associated with lower response rates. Children (or their proxies), particularly those from low-income households, were less likely to return measures. 16 Younger and minority participants may respond better to online collection versus postal data collection. 17 Among patients who completed our postparticipation (10) questionnaire, those indicating a preference for electronic PRO collection had a median age of 30 years, whereas the median age was 53 years for those who preferred paper and pencil. Others have reported a high success rate with electronic PRO collection, 18, 19 often with reminders to complete the survey and with direct links to the measures provided by e-mail or text. This has the additional benefits of reducing the cost to transmit and collect surveys and decreasing data-entry costs and errors. Offering both postal and electronic options in the future may enhance retention.
There was a high degree of satisfaction among the participants with the logistical aspects of this study, and few had privacy concerns. Few had concerns about direct communication with the CIBMTR to collect the measures, and this suggests a way to collect data without increasing the burden on transplant centers. Almost all patients felt that they would like to continue to complete PRO measures, even though a large proportion felt that doing so was not directly helpful to them. Several participants asked to see a compilation of the results and a comparison of their scores with others' scores. A future goal is to provide real-time results to patients, 20, 21 which they could bring to their clinic appointments; this could allow interventions if necessary 22 and perhaps increase participation for some groups.
A key finding in this study is that pretransplant scores are significantly associated with both survival and self-reported posttransplant HRQOL. This was found for both the FACT-BMT and the SF-36 PCS, which individually showed a greater discriminatory value than other more commonly used, physician-determined pretransplant scores (eg, KPS and HCT-CI). This aligns with the conclusions of a recently published secondary analysis of a prospective randomized clinical trial (the Blood and Marrow Transplant Clinical Trials Network 0902 study). 8 This study showed in a comparable population including 310 allogeneic transplant recipients that the pre-HCT PCS was strongly predictive of overall survival, with better survival in each higher quartile similar to that seen in our study. As in our study, the pre-HCT PCS was strongly correlated with the pretransplant KPS, but the latter did not predict survival as an independent factor. A singlecenter study of 409 allogeneic HCT recipients by Hamilton et al 23 showed that the Trial Outcome Index and the physical well-being subscales of the FACT-BMT were associated with mortality after transplantation. Our results extend these findings and suggest that the prognostic value of PRO measures holds true in the real-world setting of HCT across multiple centers. 7 The relatively low number of pediatric patients limits our ability to draw strong conclusions about children. However, the suggestive results support routine PRO collection as well as further research in this population. A further limitation is that we did not collect all possible post-HCT complications and correlate these with study participation.
In conclusion, these results suggest that a PRO measure before HCT may have greater predictive value for mortality than traditionally collected factors and that the collection of such data is feasible in the setting of an outcome registry, with which analyses of large representative data sets are possible. Incorporating routine pre-HCT PRO assessments is critically important to our ability to control for pretransplant factors when we are analyzing the contributions of transplant and posttransplant factors to the success of transplantation. It also suggests that the routine collection of post-HCT PROs is feasible, and this would add to our ability to understand and improve deficits in the quality of life of HCT survivors.
To make routine PRO data collection in HCT a reality, additional work should focus on the following practical questions: What is the most discriminating minimum set of questions to reduce the respondent's burden but maintain predictive value? 9 How can PRO data be integrated with clinical data to create the best prognostic index? How can electronic solutions be leveraged to collect and collate PROs directly from patients by a central registry and to match them with clinical data while maintaining security and minimizing the burden of data collection? Determining answers to these questions will facilitate the integration of routine PRO assessments into the already extensive pretransplant and posttransplant evaluations that transplant patients undergo.
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